SCHEMBL25025916

SCHEMBL25025916

CC1(C(=O)Nc2c[nH]c3ccc(OCCc4ccc(C(F)(F)F)cc4)cc23)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.44
MTNR1B P49286 3/20 0.44
TRPV1 Q8NER1 3/20 0.44
FAAH O00519 2/20 0.44
SIRT2 Q8IXJ6 1/20 0.43
EGFR P00533 1/20 0.41
IGF1R P08069 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
PPARA Q07869 2/20 0.40
PTGES O14684 2/20 0.40
ALOX5 P09917 2/20 0.40
PPARD Q03181 1/20 0.40
PPARG P37231 1/20 0.40
CHRNA7 P36544 1/20 0.40
STING1 Q86WV6 1/20 0.39
PSEN1 P49768 1/20 0.38
KIT P10721 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25026098 0.96 TRPV1 (0.45) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL25212326 0.94 CHRNA7 (0.44) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL25025958 0.94 TRPV1 (0.43) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL30233543 0.93 MTNR1A (0.43) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL25025970 0.93 MTNR1A (0.43) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL25025957 0.93 MTNR1A (0.43) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL25024345 0.91 TRPV1 (0.42) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL25025578 0.91 MTNR1A (0.42) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL25211260 0.91 MTNR1A (0.42) MTNR1AMTNR1BTRPV1FAAHSIRT2
SCHEMBL31757551 0.91 MTNR1A (0.42) MTNR1AMTNR1BTRPV1FAAHSIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
WO-2023018781-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 MTNR1A 2205/4885MTNR1B 2787/4885TRPV1 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.